Ta. Because we focused on reasons for taking the study pill, Pedalitin permethyl ether web participants who indicated that they had never taken a study pill were removed from the get Biotin-VAD-FMK analysis.Ethics StatementThe Ethics Review Committee (ERC) at the Kenya Medical Research Institute (KEMRI) (Bondo), the Pharma-Ethics Review Board (Pretoria), and the Protection of Human Subjects Committee (PHSC) at FHI 360 in the United States reviewed and approved the research. Participants provided either verbal (Bondo) or written (Pretoria) informed consent to participate in the follow-up study. The use of verbal consent was requested and approved by the KEMRI ERC and the PHSC for the Bondo site because the research was considered minimal risk and verbal consent has been previously approved for social-behavioral research in Kenya. Study staff signed and dated an information sheet documenting that verbal consent was indeed provided by each individual; the participants’ identification number for the follow-up study was listed on the sheet. We sought and received approval by the 1471-2474-14-48 Pharma-Ethics Review Board and the PHSC for written consent for the Pretoria site based on local guidelines that required written consent. The written consent form included the same information that was included on the verbal consent information sheet; the only difference between the two documents was the signature line.Results Study Participants and Adherence ScoresFig 2 displays the total number of participants who took part in the SSIs and ACASI. For the SSIs, we interviewed 88 women in the high (n = 25), moderate (n = 31), and none/scarcePLOS fpsyg.2016.00135 ONE | DOI:10.1371/journal.pone.0125458 April 13,6 /Facilitators of Study Pill Adherence in FEM-PrEPFig 2. Sample size. doi:10.1371/journal.pone.0125458.g(n = 32) adherence groups. Among participants in the high adherence group, the median number of specimens was six (range: 1 to 13) and the composite adherence scores ranged from 2 to 5. For 84 of participants in this group, the mean composite adherence score for all visits ranged from 4.0 to 5.0. The four participants whose mean score was below 4.0 (i.e., between 3.6 and 3.9) had between 11 and 13 samples, and seven to 10 of those samples had scores of 4 and 5. For participants in the moderate group, the median number of specimens was five (range: 2 to 13) and the composite adherence scores ranged from 0 to 5. Participants’ mean composite adherence scores for all their visits ranged from 1.0 to 3.8. The three participants whose mean scores overlapped with those of participants in the high group (i.e., between 3.7 and 3.8) each had fewer available specimens (three to five) than did participants in the high group, and several of their composite adherence scores were under 4.PLOS ONE | DOI:10.1371/journal.pone.0125458 April 13,7 /Facilitators of Study Pill Adherence in FEM-PrEPACASI was completed by 224 participants. However, we excluded responses from 52 participants (23 ) who reported that they never took a study pill, leaving a sample size of 172 participants.Semi-Structured Interviews: Participants’ Own Reasons for Taking the Study PillParticipants’ description of the reasons why they took the study pill focused on two kinds of facilitators: motivating factors and adherence strategies. We grouped these facilitators into five themes: 1) participants’ support for the research, 2) HIV risk reduction, 3) routine formation and use of tools, 4) adherence counseling, and 5) partner awareness and support. Participants’ support f.Ta. Because we focused on reasons for taking the study pill, participants who indicated that they had never taken a study pill were removed from the analysis.Ethics StatementThe Ethics Review Committee (ERC) at the Kenya Medical Research Institute (KEMRI) (Bondo), the Pharma-Ethics Review Board (Pretoria), and the Protection of Human Subjects Committee (PHSC) at FHI 360 in the United States reviewed and approved the research. Participants provided either verbal (Bondo) or written (Pretoria) informed consent to participate in the follow-up study. The use of verbal consent was requested and approved by the KEMRI ERC and the PHSC for the Bondo site because the research was considered minimal risk and verbal consent has been previously approved for social-behavioral research in Kenya. Study staff signed and dated an information sheet documenting that verbal consent was indeed provided by each individual; the participants’ identification number for the follow-up study was listed on the sheet. We sought and received approval by the 1471-2474-14-48 Pharma-Ethics Review Board and the PHSC for written consent for the Pretoria site based on local guidelines that required written consent. The written consent form included the same information that was included on the verbal consent information sheet; the only difference between the two documents was the signature line.Results Study Participants and Adherence ScoresFig 2 displays the total number of participants who took part in the SSIs and ACASI. For the SSIs, we interviewed 88 women in the high (n = 25), moderate (n = 31), and none/scarcePLOS fpsyg.2016.00135 ONE | DOI:10.1371/journal.pone.0125458 April 13,6 /Facilitators of Study Pill Adherence in FEM-PrEPFig 2. Sample size. doi:10.1371/journal.pone.0125458.g(n = 32) adherence groups. Among participants in the high adherence group, the median number of specimens was six (range: 1 to 13) and the composite adherence scores ranged from 2 to 5. For 84 of participants in this group, the mean composite adherence score for all visits ranged from 4.0 to 5.0. The four participants whose mean score was below 4.0 (i.e., between 3.6 and 3.9) had between 11 and 13 samples, and seven to 10 of those samples had scores of 4 and 5. For participants in the moderate group, the median number of specimens was five (range: 2 to 13) and the composite adherence scores ranged from 0 to 5. Participants’ mean composite adherence scores for all their visits ranged from 1.0 to 3.8. The three participants whose mean scores overlapped with those of participants in the high group (i.e., between 3.7 and 3.8) each had fewer available specimens (three to five) than did participants in the high group, and several of their composite adherence scores were under 4.PLOS ONE | DOI:10.1371/journal.pone.0125458 April 13,7 /Facilitators of Study Pill Adherence in FEM-PrEPACASI was completed by 224 participants. However, we excluded responses from 52 participants (23 ) who reported that they never took a study pill, leaving a sample size of 172 participants.Semi-Structured Interviews: Participants’ Own Reasons for Taking the Study PillParticipants’ description of the reasons why they took the study pill focused on two kinds of facilitators: motivating factors and adherence strategies. We grouped these facilitators into five themes: 1) participants’ support for the research, 2) HIV risk reduction, 3) routine formation and use of tools, 4) adherence counseling, and 5) partner awareness and support. Participants’ support f.
Posted inUncategorized